Which are the causes of Sanfilippo Syndrome?

TL;DR: Sanfilippo Syndrome, or mucopolysaccharidosis type III (MPS III), is a rare, life-limiting genetic metabolic disorder caused by the body's inability to properly break down complex sugar chains called heparan sulfate. Because the enzymes required to recycle these sugars are deficient, the material accumulates within cells throughout the body, leading to progressive damage, particularly in the nervous system.

What is the underlying cause of Sanfilippo Syndrome?

At its core, Sanfilippo Syndrome is a lysosomal storage disorder. Think of the cell as a busy factory and the lysosome as its recycling center. In a healthy person, specific enzymes act like workers in this recycling center, breaking down large molecules—specifically heparan sulfate—into smaller, usable pieces. In individuals with Sanfilippo Syndrome, one of these essential "workers" is missing or defective. Because the recycling process is stalled, the heparan sulfate builds up like trash in a facility, eventually overflowing and toxic to the cell's function, causing the cognitive decline, behavioral challenges, and physical symptoms associated with the disease.

Is Sanfilippo Syndrome hereditary?

Yes, Sanfilippo Syndrome is an inherited condition passed from parents to children through an autosomal recessive pattern. This means that for a child to be born with the disease, both parents must be carriers of a mutation in the same gene. Carriers do not typically show symptoms themselves, but each child of two carrier parents has a 25% chance of inheriting the condition. There are four distinct subtypes of Sanfilippo Syndrome (types A, B, C, and D), each corresponding to a mutation in a different gene involved in the heparan sulfate degradation pathway:

• Type A: Mutations in the SGSH gene.


• Type B: Mutations in the NAGLU gene.


• Type C: Mutations in the HGSNAT gene.


• Type D: Mutations in the GNS gene.

Are there environmental or external risk factors?

Current medical research confirms that Sanfilippo Syndrome is strictly a genetic condition. There are no known environmental triggers, lifestyle choices, or external factors that cause the disease. It is not caused by anything the parents did or did not do during pregnancy. While the primary cause is the genetic mutation, researchers are currently studying how the secondary buildup of other metabolic substances, such as gangliosides, contributes to the severity of the neurological symptoms. This is why therapies like Miglustat are sometimes explored—not to fix the primary genetic cause, but to mitigate the secondary damage caused by the metabolic imbalance.

What is the status of research into the etiology of Sanfilippo Syndrome?

While the genetic cause of Sanfilippo Syndrome is well-understood, researchers are heavily focused on understanding the downstream effects of the disease to improve clinical outcomes. Because the condition affects multiple systems, including the digestive, respiratory, and nervous systems, scientists are investigating how to deliver functional enzymes directly to the brain, which is protected by the blood-brain barrier. Current clinical trials are exploring gene therapies designed to provide the body with the "instructions" to produce the missing enzymes, as well as substrate reduction therapies that aim to slow down the production of heparan sulfate so the overwhelmed system can better manage it.

Next steps

• Consult with a metabolic specialist or a clinical geneticist to confirm the specific subtype of Sanfilippo Syndrome affecting your loved one.


• Join the DiseaseMaps.org community to connect with 114 other members who are navigating the challenges of Sanfilippo Syndrome and sharing their experiences with clinical trials and care.


• Stay updated on the latest clinical trial registries at ClinicalTrials.gov to see if your family member may be eligible for emerging gene or enzyme replacement therapies.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Mucopolysaccharidosis Type III.


• Orphanet: Mucopolysaccharidosis type 3.


• OMIM (Online Mendelian Inheritance in Man): MPS3A, MPS3B, MPS3C, and MPS3D entries.


• National MPS Society: Information and resources on Sanfilippo Syndrome.